Christopher A Lazarski
Overview
Explore the profile of Christopher A Lazarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keller M, Hanley P, Chi Y, Aguayo-Hiraldo P, Dvorak C, Verneris M, et al.
Nat Commun
. 2024 Apr;
15(1):3258.
PMID: 38637498
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed...
2.
Keller M, Schattgen S, Chandrakasan S, Allen E, Jensen-Wachspress M, Lazarski C, et al.
Nat Commun
. 2024 Mar;
15(1):2749.
PMID: 38553461
Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare...
3.
Lazarski C, Hanley P
Cytotherapy
. 2023 Nov;
26(2):103-112.
PMID: 37943204
Quality control testing and analytics are critical for the development and manufacture of cell and gene therapies, and flow cytometry is a key quality control and analytical assay that is...
4.
Chaudhry K, Geiger A, Dowlati E, Lang H, Sohai D, Hwang E, et al.
Mol Ther Methods Clin Dev
. 2022 Nov;
27:415-430.
PMID: 36381305
Cord blood (CB)-derived natural killer (NK) cells that are genetically engineered to express a chimeric antigen receptor (CAR) are an attractive off-the-shelf therapy for the treatment of cancer, demonstrating a...
5.
Durkee-Shock J, Lazarski C, Jensen-Wachspress M, Zhang A, Son A, Kankate V, et al.
Mol Ther Methods Clin Dev
. 2022 May;
25:439-447.
PMID: 35506060
Adoptive T cell immunotherapy has been used to restore immunity against multiple viral targets in immunocompromised patients after bone-marrow transplantation and has been proposed as a strategy for preventing coronavirus...
6.
Conway S, Lazarski C, Field N, Jensen-Wachspress M, Lang H, Kankate V, et al.
Front Immunol
. 2022 Feb;
12:793197.
PMID: 35116027
Background: Despite similar rates of infection, adults and children have markedly different morbidity and mortality related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Compared to adults, children have infrequent severe...
7.
Lazarski C, Toner K, Keller M, Luban N, Young P, Bollard C, et al.
Blood Transfus
. 2021 Aug;
19(6):456-466.
PMID: 34369863
Background: Leukoreduction to eliminate mononuclear cells within blood products is necessary to prevent graft-versus-host disease after transfusion. Published reports document low concentrations of mononuclear cells leftover in fresh-frozen plasma products,...
8.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V, Lang H, Lazarski C, et al.
J Clin Immunol
. 2021 May;
41(6):1146-1153.
PMID: 33983545
Immunocompromised patients, including those with inborn errors of immunity (IEI), may be at increased risk for severe or prolonged infections with SARS-CoV-2 (Zhu et al. N Engl J Med. 382:727-33,...
9.
Keller M, Harris K, Jensen-Wachspress M, Kankate V, Lang H, Lazarski C, et al.
Blood
. 2020 Dec;
136(25):2905-2917.
PMID: 33331927
T-cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in recovered patients, and may be important for immunity following infection and vaccination as well as for...
10.
Harris K, Horn S, Grant M, Lang H, Sani G, Jensen-Wachspress M, et al.
Front Immunol
. 2020 Oct;
11:575977.
PMID: 33123159
Human Parainfluenza Virus-3 (HPIV3) causes severe respiratory illness in immunocompromised patients and lacks approved anti-viral therapies. A phase I study of adoptively transferred virus-specific T-cells (VSTs) targeting HPIV3 following bone...